Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | RORA | P35398 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | RORB | Q92753 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8107081 | 0.85 | MAPK1 (0.64) | TSHRMAPK1HSD17B10KMT2AESR1 | |
| SCHEMBL6086563 | 0.79 | HDAC6 (0.48) | HDAC6TSHRHSD17B10KMT2AALDH1A1 | |
| SCHEMBL7541154 | 0.72 | ALDH1A1 (0.56) | HDAC6TSHRMAPK1HSD17B10KMT2A | |
| SCHEMBL7538012 | 0.71 | HDAC6 (0.48) | HDAC6TSHRMAPK1HSD17B10ALDH1A1 | |
| SCHEMBL18531401 | 0.70 | HDAC6 (0.44) | HDAC6TSHRMAPK1HSD17B10KMT2A | |
| SCHEMBL6086664 | 0.68 | CA1 (0.58) | HDAC6MAPK1LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL6088955 | 0.67 | CA1 (0.57) | HDAC6MAPK1LMNAALDH1A1 | |
| SCHEMBL6087539 | 0.66 | RAB9A (0.45) | TSHRESR1LMNAALDH1A1ALOX15 | |
| SCHEMBL8629125 | 0.66 | HDAC6 (0.40) | HDAC6TSHRMAPK1HSD17B10KMT2A | |
| SCHEMBL22909271 | 0.65 | CA1 (0.43) | HDAC6LMNAALDH1A1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138418-B2 | For therapy of atherosclerosis and hypercholesterolemia; 5-Pentafluorophenylsulfonamidoindazole for example; increasing LDL receptor gene expression in a cell | AMGEN, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-6962929-B2 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. (US) | 2005-11-08 | — | — | US | disclosed |
| EP-0939627-B1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-0896533-B1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030162817-A1 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1334719-A2 | Pentafluorobenzenesulfonamides and analogs | TULARIK, INC. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6482860-B1 | such as batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene), use as antiproliferative agents to treat cancer | TULARIK INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020143036-A1 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. | 2002-10-03 | — | — | US | disclosed |
| US-6316484-B1 | FOR THERAPY OR PROPHYLAXIS OF ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA | TULARIK INC. | 2001-11-13 | — | — | US | disclosed |
| US-6121304-A | SUCH AS 1-(PENTAFLUOROPHENYLSULFONYL)INDOLE; USEFUL IN TREATING ATHEROSCLEROSIS AND HYPERCHOLESTEROLERNIA | TULARIK INC (US) | 2000-09-19 | — | — | US | disclosed |
| US-5880151-A | TREATING OR PREVENTING DISEASE CHARACTERIZED BY HIGH LEVELS OF LOW DENSITY LIPOPROTEIN PARTICLES OR CHOLESTEROL IN BLOOD | TULARIK INC. (US) | 1999-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162817-A1 | Pentafluorobenzenesulfonamides and analogs | FGFR1, FPR1, FGF1 | HDAC6 1077/4885TSHR 1857/4885MAPK1 163/4885 |
| US-20020143036-A1 | Pentafluorobenzenesulfonamides and analogs | FFAR1, PCSK9, PFAS | HDAC6 1204/4885TSHR 1540/4885MAPK1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.